Alexion, AstraZeneca Rare Disease has received approval from the USFDA for Koselugo (selumetinib), an oral, selective MEK ...
The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...
The Food and Drug Administration (FDA) has approved Koselugo ® (selumetinib) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback